Analysis of advanced cancer patients treated with immune-checkpoint inhibitors shows that tumor mutational burden, as assessed by targeted next-generation sequencing, predicts survival after immunotherapy across multiple cancer types.
- Robert M. Samstein
- Chung-Han Lee
- Luc G. T. Morris
